In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics – NVIDIA Technical Blog News and tutorials for developers, data scientists, and IT admins 2025-03-27T16:00:00Z http://www.open-lab.net/blog/feed/ Vega Shah <![CDATA[In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics]]> http://www.open-lab.net/blog/?p=92757 2024-12-12T19:38:30Z 2024-12-03T18:00:00Z Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range...]]> Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range...Image shows a 3D molecular structure of a protein, most likely an antibody, visualized using a ribbon diagram, with the classic Y-shaped configuration characteristic of antibodies.

Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders. Their specificity reduces the likelihood of off-target effects, making them safer and often more effective than small-molecule drugs for complex conditions. As a result��

Source

]]> 0 ���˳���97caoporen����